Newsroom

MedinCell’s partner Teva provides additional information regarding the New Drug Application for mdc-IRM

May 3, 2022

May 3, 2022

MedinCell provides additional information regarding the new drug application for mdc-IRM

April 19, 2022

April 19, 2022

Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM

April 19, 2022

April 19, 2022

MedinCell: inclusion of first participants in new Covid-19 prophylaxis clinical trial SAIVE

March 28, 2022

March 28, 2022

Publication of the 2022 financial calendar

January 13, 2022

January 13, 2022

Intra-articular delivery of full-length antibodies through the use of an in situ forming depot

December 12, 2021

December 12, 2021

MedinCell publishes its financial results and activity report for the first half of 2021-2022

December 8, 2021

December 8, 2021

Videoconference • Half-Year results

December 8, 2021

Videoconference and publication of the 2021-2022 Half-Year Results, on December 8, 2021

December 2, 2021

December 2, 2021

MedinCell receives €4 million in funding from Bpifrance and within the framework of the French Recovery Plan (Plan France Relance)

December 1, 2021

December 1, 2021

Videoconference • mdc-IRM Phase 3 results

November 4, 2021

Phase 3 data of mdc-IRM, first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia: – Prolonged time to impending relapse – Decreased risk of relapse – Increased chance of clinical stability

November 1, 2021

November 1, 2021